Stockholders’ Equity (Details)
|
|
|
|
3 Months Ended |
6 Months Ended |
12 Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jan. 05, 2026
shares
|
Jun. 17, 2024
USD ($)
shares
|
Apr. 17, 2024
USD ($)
shares
|
Jun. 30, 2026
USD ($)
$ / shares
shares
|
Mar. 31, 2026
shares
|
Dec. 31, 2025
USD ($)
$ / shares
shares
|
Jun. 30, 2025
USD ($)
shares
|
Dec. 31, 2024
USD ($)
$ / shares
shares
|
Jun. 30, 2026
USD ($)
$ / shares
shares
|
Jun. 30, 2025
USD ($)
|
Dec. 31, 2025
USD ($)
$ / shares
shares
|
Dec. 31, 2024
USD ($)
$ / shares
shares
|
Jun. 23, 2026
shares
|
[1] |
Apr. 28, 2026
shares
|
[1] |
Feb. 26, 2026
shares
|
[1] |
Dec. 30, 2025
shares
|
[2] |
Dec. 02, 2025
shares
|
[2] |
Nov. 11, 2025
shares
|
[2] |
Sep. 15, 2025
shares
|
[2] |
Jul. 17, 2025
shares
|
[2] |
Jun. 16, 2025
shares
|
[2] |
Jun. 05, 2025
shares
|
[2] |
Jan. 04, 2024
$ / shares
shares
|
Dec. 31, 2023
$ / shares
shares
|
Sep. 13, 2023
shares
|
Aug. 31, 2023
shares
|
Aug. 14, 2023
shares
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock, par value (in Dollars per share) | $ / shares |
|
|
|
$ 0.0001
|
|
|
$ 0.0001
|
|
|
$ 0.0001
|
$ 0.0001
|
|
|
$ 0.0001
|
|
$ 0.0001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock, shares authorized |
|
|
|
3,254,475,740
|
|
|
3,254,475,740
|
|
|
3,254,475,740
|
3,254,475,740
|
|
|
3,254,475,740
|
|
3,254,475,740
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock, voting rights |
|
|
|
|
|
|
|
|
|
|
Common Stock are entitled
to vote on a 1 share/1 vote basis
|
|
|
Common Stock are entitled to vote on
a 1 share/1 vote basis
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock shares outstanding |
|
|
|
976,997,116
|
|
|
956,997,116
|
|
|
956,997,116
|
976,997,116
|
|
|
956,997,116
|
|
956,997,116
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock shares issued |
|
|
|
976,997,116
|
|
|
956,997,116
|
|
|
956,997,116
|
976,997,116
|
|
|
956,997,116
|
|
956,997,116
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Options outstanding |
|
|
|
|
|
|
184,264,323
|
|
|
184,264,323
|
|
|
|
184,264,323
|
|
184,264,323
|
|
|
|
|
|
|
|
|
|
|
|
163,142,084
|
|
|
|
| Share based compensation (in Dollars) | $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Options to purchase common shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21,122,239
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred Stock, Shares Authorized |
|
|
|
12,500,000
|
|
|
12,500,000
|
|
|
12,500,000
|
12,500,000
|
|
|
12,500,000
|
|
12,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred stock, par value (in Dollars per share) | $ / shares |
|
|
|
$ 0.0001
|
|
|
$ 0.0001
|
|
|
$ 0.0001
|
$ 0.0001
|
|
|
$ 0.0001
|
|
$ 0.0001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred stock outstanding |
|
|
|
5,847,937
|
|
|
5,847,937
|
|
|
5,847,937
|
5,847,937
|
|
|
5,847,937
|
|
5,847,937
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants issuance |
|
|
|
279,000,000
|
[1] |
|
262,500,000
|
[1],[2] |
|
|
279,000,000
|
[1] |
|
262,500,000
|
[1],[2] |
|
13,636,364
|
63,461,538
|
49,180,328
|
21,067,416
|
18,750,000
|
37,974,684
|
27,906,977
|
15,789,474
|
24,193,548
|
75,000,000
|
|
|
|
|
|
| Fair value of warrants issuance (in Dollars) | $ |
|
|
|
$ 43,048
|
|
|
$ (29,448)
|
|
$ (1,903)
|
|
$ 25,348
|
|
$ (1,903)
|
$ (29,448)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate fair value (in Dollars) | $ |
|
$ 170,920
|
$ 35,814
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Consecutive trading days |
|
|
|
|
|
|
|
|
|
|
|
|
|
20 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of the warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
300.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Trading day |
|
|
|
|
|
|
|
|
|
|
|
|
|
20 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Trading period equals or exceeds amount (in Dollars) | $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Redeemed price per share (in Dollars per share) | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Closing stock price per share (in Dollars per share) | $ / shares |
|
|
|
|
|
|
$ 0.01
|
|
|
$ 0.0056
|
|
|
|
$ 0.01
|
|
$ 0.0056
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.01
|
|
|
|
| Share-base compensation (in Dollars) | $ |
|
|
|
|
|
|
$ 39,170
|
|
15,977
|
$ 2,246,033
|
|
|
39,170
|
$ 39,170
|
|
$ 2,246,033
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of stock option (in Dollars) | $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 84,828
|
|
$ 1,612,841
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Weighted average grant date fair value for options granted (in Dollars per share) | $ / shares |
|
|
|
|
|
|
$ 0.01
|
|
|
$ 0.01
|
|
|
|
$ 0.01
|
|
$ 0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Board of Directors Chairman [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants issuance |
|
|
10,454,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants issuance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
946,652,602
|
| Warrants exercise price (in Dollars per share) | $ / shares |
|
|
|
|
|
|
0.033
|
|
|
|
|
|
|
0.033
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Closing stock price per share (in Dollars per share) | $ / shares |
|
|
|
|
|
|
$ 0.01
|
|
|
$ 0.01
|
|
|
|
$ 0.01
|
|
$ 0.01
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.01
|
|
|
|
| Oriole Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of warrants issuance (in Dollars) | $ |
|
|
$ 35,814
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Equity Incentive Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Options outstanding |
|
|
|
163,142,084
|
|
|
|
|
|
|
163,142,084
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
163,142,084
|
|
| Share based compensation (in Dollars) | $ |
|
|
|
|
|
|
|
|
$ 15,977
|
|
|
|
$ 39,170
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock, par value (in Dollars per share) | $ / shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.0001
|
|
|
|
|
| Shares of common stock |
|
|
|
|
|
20,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common shares issuable per share converted |
|
|
|
|
|
|
100
|
|
|
|
|
|
|
100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Converted shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
461,542,570
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Board of Directors Chairman [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Options to purchase common shares |
|
21,122,239
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of warrants issuance |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,181,817
|
|
|
| Measurement Input, Expected Term [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant expected life |
|
5 years
|
5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measurement Input, Price Volatility [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value |
|
76.58
|
77.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measurement Input, Risk Free Interest Rate [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value |
|
4.3
|
4.62
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measurement Input, Expected Dividend Rate [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value |
|
0
|
0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measurement Input, Share Price [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value |
|
0.01
|
0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measurement Input, Exercise Price [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value |
|
0.0037
|
0.033
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| General and Administrative Expenses [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share based compensation (in Dollars) | $ |
|
$ 170,920
|
|
|
|
|
|
|
|
|
|
|
|
$ 39,170
|
|
$ 1,673,270
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Research and Development Expenses [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share based compensation (in Dollars) | $ |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
$ 572,763
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| American Academy of Facial Esthetics LLC [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock prepayment |
200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| American Academy of Facial Esthetics LLC [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares of common stock |
20,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Minimum [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock, shares authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
500,000,000
|
|
|
|
|
| Maximum [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock, shares authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,254,475,740
|
|
|
|
|
| Convertible Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred stock, par value (in Dollars per share) | $ / shares |
|
|
|
|
|
|
$ 1.1
|
|
|
|
|
|
|
$ 1.1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Series A Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Convertible into conversion price (in Dollars per share) | $ / shares |
|
|
|
|
|
|
$ 0.011
|
|
|
|
|
|
|
$ 0.011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common shares issuable per share converted |
|
|
|
100
|
|
|
|
|
|
|
100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Series A Preferred Stock [Member] | Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stockholders’ Equity (Details) [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares of common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Converted shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4,615,426)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|